Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509899 · ClinicalTrials.gov registry record · Phase 1
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
A Phase 1 study of Myelofibrosis and Polycythemia Vera, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
- 2
- Study locations
NCT00509899: Completed Phase 1 study of Myelofibrosis and Polycythemia Vera, sponsored by Incyte Corporation.
NCT00509899 is a Phase 1 study of Myelofibrosis and Polycythemia Vera that has completed, run by Incyte Corporation. The registered enrollment target is 154 participants, below the 193-participant average among 61 other Myelofibrosis trials with a reported enrollment target (20% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509899, a Phase 1 study of Myelofibrosis and Polycythemia Vera, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
- 2
- Study locations
Study Summary
To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia Myelofibrosis (PET-MF).
Primary Outcome
Treatment-Emergent AEs are events occurring after first drug administration or worsened from baseline. Treatment-Related AEs are those with a definite, probable, possible or missing causality. A serious AE is a medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is a medical event requiring intervention to prevent
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (2)
Minnesota
- - Rochester
Texas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2007-06 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
What the finished NCT00509899 record still lists
NCT00509899 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 193-participant average among 61 other Myelofibrosis trials with a reported enrollment target (20% lower).
The record links to 3 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT00509899 reports a single indexed study location in Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT00509899 about?
NCT00509899 is a clinical study titled "Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis". To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia Myelofibrosis (PET-MF).
What is the current status of trial NCT00509899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2007-06. Estimated completion is 2017-02.
What conditions does trial NCT00509899 study?
This clinical trial studies the following conditions: Myelofibrosis, Polycythemia Vera, Thrombocytosis.
What interventions are being tested in trial NCT00509899?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT00509899?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00509899 being conducted?
This trial has 2 study locations across Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00509899's enrollment target sits among peer trials
154 16th of 61 higher than 46 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia